Lv4
676 积分 2025-04-02 加入
Targeted LC–MS/MS profiling highlights altered cerebrospinal fluid glutathione in cancer patients with CNS metastases
25天前
已完结
Abstract PS1-05-03: Vitiligo-like Lesions Associated with CDK4/6 Inhibitors in Metastatic HR+/HER2− Breast Cancer: Multiple case reports from a Brazilian experience
1个月前
已关闭
Vitiligo-like leukoderma following treatment with cyclin-dependent kinase 4/6 inhibitors - analysis of clinicopathologic and immunohistochemical findings
1个月前
已完结
Adagrasib-induced photodistributed hyperpigmentation: Two case reports and pathogenetic hypothesis
3个月前
已关闭
Deep exploration of sotorasib-related hepatobiliary AEs: Based on FDA Adverse Event reporting system
3个月前
已完结
Two first-generation KRAS inhibitor safety profiles: a disproportionality analysis of individual reports from the FDA adverse event reporting system
3个月前
已完结
P3.12.18 Vebreltinib Plus EGFR-TKI in EGFR-Mutated NSCLC With MET Amplification And/Or Overexpression After Failure on EGFR-TKI: A Retrospective Study
4个月前
已关闭
P3.09.07 Local MDT Improve the Survival of Leptomeningeal Metastasis in NSCLC With EGFR Mutation From the CLM-Tree Registry
4个月前
已关闭
EGFR-TKI plus chemotherapy versus tki monotherapy in advanced EGFR-Mutant NSCLC with high PD-L1 expression: a real-world retrospective study
4个月前
已完结
213eTiP First-line oral vinorelbine plus furmonertinib in refractory epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC): A multicenter, non-randomized, two-cohort study
4个月前
已关闭